PFE
Stock Details
PFE is Pfizer Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 51.32$. Average daily volumn in 3 months 28.09M. Market cap 294.40B
Stock symbol : PFE. Exchange : NYSE. Currency : USD Lastest price : 52.47$. Total volume : 29.52M. Market state POSTPOST Click reload if you want to check the lastest price on market!!!
Pfizer Inc. (PFE)
Last Price
52.47$Change
1.82Volume
29.52M
| Previous Close | 50.65 |
| Open | 51.26 |
| Day Range | 51.13-52.70 |
| Bid | 52.47 x 1.8k |
| Ask | 52.48 x 2.2k |
| Volume | 29.52M |
| Average Volume | 28.09M |
| Market Cap | 294.4B |
| Beta | 0.71 |
| 52 Week Range | 38.48-61.71 |
| Trailing P/E | 12.03 |
| Foward P/E | 1.00 |
| Dividend (Yield %) | 3.16% |
| Ex-Dividend Date | 2022-05-12 |
Financial Details
Organization
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 trea... tment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Market Cap:
294.40BRevenue:
81.29BTotal Assets:
181.48BTotal Cash:
1.94B
News about "Pfizer Inc."
Pfizer will give $107,000 to Colorado to settle lawsuit over failed coupons
Source from : Denver Post on MSN.com - 12 hours ago
About 1,500 Coloradans will receive a refund from Pfizer after the pharmaceutical company failed to honor coupons for three medications, according to the Colorado Attorney General’s Office. Pfizer has ...See details»
Pfizer, NIH Mulling Study For Longer Paxlovid Course To Combat Reinfections
Source from : YAHOO!Finance - 1 days ago
The U.S. National Institutes of Health and Pfizer Inc (NYSE: PFE) are discussing testing a longer course of COVID-19 antiviral treatment Paxlovid, required to prevent reinfections, White House Chief ...See details»
Pfizer a Top 25 Dividend Giant With 3.17% Yield (PFE)
Source from : Nasdaq - 1 days ago
Pfizer Inc (Symbol: PFE) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a stunning $33.49B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a ...See details»
CDC advisers recommend Pfizer COVID-19 booster shot for kids ages 5 to 11
Source from : MarketWatch - 1 days ago
Experts advising the CDC on vaccines recommended that children age 5 to 11 receive the newly authorized COVID booster shot from Pfizer Inc. and BioNTech SE.See details»
Pfizer's tight Paxlovid rein symies drug combination research
Source from : Crain's New York - 2 days ago
Pfizer hasn’t started any combination trials in people, and a review of the clinicaltrials.gov database shows no outpatient studies combining Paxlovid, the mainstay U.S. Covid therapy, with other ...See details»
$2.07 Earnings Per Share Expected for Pfizer Inc. (NYSE:PFE) This Quarter
Source from : Defense World - 3 days ago
Wall Street analysts expect that Pfizer Inc. (NYSE:PFE – Get Rating) will post $2.07 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have ...See details»
CDC Recommends Pfizer/BioNTech COVID-19 Booster Shots For Kids Aged 5-11 Years
Source from : YAHOO!Finance - 22 hours ago
The Centers for Disease Control and Prevention recommended that children ages 5 to 11 receive the newly authorized COVID-19 booster shot from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX).See details»
Pfizer Inc. (NYSE: PFE) Finds That Paxlovid Cannot Prevent COVID-19 Infection
Source from : MarketWatch - 8 days ago
Pfizer Inc. (NYSE: PFE) has found that its Paxlovid pill might not effectively prevent COVID-19 in people who have come in contact with infected individuals. Paxlovid is an oral drug which the Food ...See details»
Switzerland buys Pfizer's COVID-19 antiviral Paxlovid
Source from : Nasdaq - 21 hours ago
Switzerland signed a contract to buy Pfizer's anti-viral drug Paxlovid to treat Covid-19, it said on Friday. BERLIN, May 20 (Reuters) - Switzerland signed a contract to buy Pfizer's anti-viral drug ...See details»
Rollout of Pfizer COVID-19 Vaccine Saved Lives, Health Care Dollars
Source from : St. Louis Post-Dispatch - 1 days ago
Manuela Di Fusco, from Pfizer Inc. in New York City, and colleagues developed a combined Markov decision tree model to compare clinical and economic outcomes of the Pfizer-BioNTech COVID-19 vaccine ...See details»
Pfizer to spend $11.6B on migraine treatment maker Biohaven
Source from : Associated Press - 10 days ago
Pfizer is starting to put its COVID-19 cash influx to use by spending $11.6 billion to venture deeper into a new treatment area. The New York vaccine and cancer drug maker said Tuesday it will use ...See details»
CDC gives final approval for Pfizer's 5-11 kids booster shot
Source from : Crain's Detroit - 1 days ago
Younger children across the U.S. are now eligible to receive a COVID-19 booster shot developed by Pfizer Inc. and BioNTech SE after the head of the Centers for Disease Control and Prevention granted ...See details»
Pfizer Inc. (NYSE:PFE) Expected to Post Quarterly Sales of $30.75 Billion
Source from : Defense World - 5 days ago
Brokerages predict that Pfizer Inc. (NYSE:PFE – Get Rating) will announce sales of $30.75 billion for the current quarter, according to Zacks. Three analysts have made estimates for Pfizer’s earnings.See details»
Pfizer’s Covid-19 Booster Cleared for 5- to 11-Year-Olds
Source from : Wall Street Journal - 3 days ago
The authorization by U.S. health regulators expands booster access to about 28 million youngsters.See details»